Transcripta Bio raised $24 million to advance AI-driven neurological disease therapeutics focused on modulating gene expression signatures. The company says it will use patient-derived single-cell RNA-seq datasets to define disease signatures, build a “drug atlas” capturing transcriptome-wide dose-response profiles, and train models to identify small molecules that can shift those signatures. Transcripta plans to use the funding to support IND-enabling studies and clinical preparation across programs that include autism spectrum disorder (ASD) and facioscapulohumeral muscular dystrophy (FSHD). The company also brought in Mayo Clinic and Omnimed as investors, alongside JAZZ Venture Partners and BlueYard Capital. The round underscores investor preference for platform companies attempting to reduce translational uncertainty early by grounding discovery in transcriptome perturbation datasets tied to relevant cell contexts.